About Cidara Therapeutics, Inc.
Cidara Therapeutics, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of long-acting anti-infectives for the treatment and prevention of infectious diseases and oncology in the United States. The company's lead product candidate is rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates.
Quality Assessment
Cidara Therapeutics, Inc. is a high-risk healthcare company with a Compass Score of 4. Poor quality metrics and high risk. Not one for conservative investors.
Score Breakdown
The Compass Score is based on 6 quality factors identified by academic research.
Click any factor to see detailed metrics
Valuation Metrics
Click any metric for details
Wall Street View
Catalyst Signal
PlusRecent earnings beats and analyst-upgrade momentum. How it works
Analyst Track Record
Financial Health
PlusClick any metric for details
Growth Projections
PlusTechnical Overview
Click any metric for details
Similar High-Quality Stocks
LXRX
Lexicon Pharmaceuticals, Inc.
MRVI
Maravai LifeSciences Holdings, Inc.
BLLN
BillionToOne, Inc.
DAWN
Day One Biopharmaceuticals, Inc.
IDYA
IDEAYA Biosciences, Inc.
ENTO
Entero Therapeutics, Inc.
Important Disclaimer
The Compass Score is for educational purposes only and does not constitute financial advice. Past performance does not guarantee future results. Always do your own research and consider consulting a financial advisor before making investment decisions.
Unlock Detailed Metrics
Upgrade to Plus to see the actual financial values behind each quality factor.
- See exact ROA, cash flow ratios, and more
- Unlimited stock views + smart search
- Export data to CSV
- Golden Stocks + analyst coverage
Cancel anytime